Powell Investment Advisors LLC Trims Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Powell Investment Advisors LLC decreased its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 50.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 25,000 shares of the company’s stock after selling 25,610 shares during the period. Powell Investment Advisors LLC’s holdings in Xeris Biopharma were worth $85,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in XERS. China Universal Asset Management Co. Ltd. lifted its holdings in Xeris Biopharma by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock valued at $107,000 after acquiring an additional 2,954 shares during the last quarter. GPS Wealth Strategies Group LLC lifted its stake in shares of Xeris Biopharma by 6.2% in the 4th quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company’s stock valued at $227,000 after purchasing an additional 3,900 shares during the last quarter. Goldstein Advisors LLC lifted its stake in shares of Xeris Biopharma by 19.7% in the 3rd quarter. Goldstein Advisors LLC now owns 30,425 shares of the company’s stock valued at $87,000 after purchasing an additional 5,000 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Xeris Biopharma by 10.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 57,805 shares of the company’s stock worth $130,000 after purchasing an additional 5,291 shares during the period. Finally, Janney Montgomery Scott LLC increased its position in shares of Xeris Biopharma by 31.4% during the 4th quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock worth $78,000 after purchasing an additional 5,500 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Analysts Set New Price Targets

XERS has been the topic of a number of recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Piper Sandler lowered shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a report on Monday, November 11th. Finally, HC Wainwright lifted their target price on shares of Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a report on Monday, November 11th.

Xeris Biopharma Stock Down 1.9 %

NASDAQ XERS opened at $3.55 on Monday. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.69 and a 1-year high of $3.87. The stock has a 50-day moving average of $3.45 and a two-hundred day moving average of $3.08.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.